Research programme: cancer therapeutics - Mirna/RXiAlternative Names: RNAi-based cancer therapies - Mirna/RXi Pharmaceuticals
Latest Information Update: 05 May 2016
At a glance
- Originator Mirna Therapeutics; RXi Pharmaceuticals Corporation
- Developer Mirna Therapeutics; RXi Pharmaceuticals
- Class Small interfering RNA; Small molecules
- Mechanism of Action RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer